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Abstract
Background: Metal chelators have gained much attention as potential anti-cancer agents. However, the effects of
chelators are often linked solely to their capacity to bind iron while the potential complexation of other trace
metals has not been fully investigated. In present study, we evaluated the effects of various lipophilic
aroylhydrazone chelators (AHC), including novel compound HNTMB, on various ovarian cancer cell lines (SKOV-3,
OVCAR-3, NUTU-19).
Methods: Cell viability was analyzed via MTS cytotoxicity assays and NCI60 cancer cell growth screens. Apoptotic
events were monitored via Western Blot analysis, fluorescence microscopy and TUNEL assay. FACS analysis was
carried out to study Cell Cycle regulation and detection of intracellular Reactive Oxygen Species (ROS)
Results: HNTMB displayed high cytotoxicity (IC50 200-400 nM) compared to previously developed AHC (oVtBBH,
HNtBBH, StBBH/206, HNTh2H/315, HNI/311; IC50 0.8-6 μM) or cancer drug Deferoxamine, a hexadentate iron-
chelator (IC50 12-25 μM). In a NCI60 cancer cell line screen HNTMB exhibited growth inhibitory effects with
remarkable differences in specificity depending on the cell line studied (GI50 10 nM-2.4 μM). In SKOV-3 ovarian
cancer cells HNTMB treatment led to chromatin fragmentation and activation of the extrinsic and intrinsic
pathways of apoptosis with specific down-regulation of Bcl-2. HNTMB caused delayed cell cycle progression of
SKOV-3 through G2/M phase arrest. HNTMB can chelate iron and copper of different oxidation states. Complexation
with copper lead to high cytotoxicity via generation of reactive oxygen species (ROS) while treatment with iron
complexes of the drug caused neither cytotoxicity nor increased ROS levels.
Conclusions: The present report suggests that both, non-complexed HNTMB as a chelator of intracellular trace-
metals as well as a cytotoxic HNTMB/copper complex may be developed as potential therapeutic drugs in the
treatment of ovarian and other solid tumors.
Background
The current treatment of a variety of tumors, including
ovarian cancer, relies on organometallic platinum com-
pounds. Ovarian cancer is the leading cause of death
from gynecologic malignancies and ranks second among
newly diagnosed gynecological cancers in the United
States [1,2]. Although most women will initially respond
to cytoreductive surgery and adjuvant paclitaxel-based
and platinum-based chemotherapy, the majority will
experience disease recurrence. While re-treatment with
a platinum-based agent is possible for some women,
overall response rates to second line chemotherapeutic
agents are 15-30% and treatment of recurrent ovarian
carcinoma is mainly directed at palliation [3-6]. Treat-
ment strategies against tumors that developed resistance
to standard chemotherapeutic agents, most notably pla-
tinum analogs, include non-platinum drugs with
increased activity and response rates. Chelating drugs
and chelator metal complexes are used for the preven-
tion, diagnosis and treatment of cancer and chelating
compounds with high affinity for iron or copper have
been suggested as potential anti-tumor agents [7]. In
previous studies the effects of chelating drugs were
often linked solely to their capacity to complex iron
while the potential complexation of other trace metals
was not discussed or analyzed. One rationale for the
anti-tumor activity of chelators is a higher Fe utilization
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by cancer cells and often elevated concentrations of
trace metals, particularly of copper, in tumor patients
[8-10].
Copper chelators such as D-penicillamine, trientine,
tetrathiomolybdate are currently being used in the treat-
ment of copper-overload disorders such as Wilson’s dis-
ease. Copper complexes such as 8-hydroxyquinoline
derivatives, pyrrolidine dithiocarbamate and clioquinol
have been reported to be cytotoxic against cancer cells
[11,12]. Copper is an essential cofactor for several extra-
cellular and a multitude of intracellular enzymes and
plays a pivotal role in cellular metabolism including
energy production (cytochrome c oxidase), intracellular
metal detoxification (Cu(I)-glutathione-complex
mediated metallothionein activity), iron detoxification
(via ceruloplasmin), connective tissue formation (lysyl
oxidase), and antioxidant defense system [Cu/Zn super-
oxide dismutase (SOD)] against ROS [13,14]. ROS are
tightly regulated in balance with cellular defensive anti-
oxidants, such as catalase and SOD, and can participate
in a multitude of cellular functions (e.g., signal transduc-
tion, platelet aggregation, immune system control, pro-
duction of energy, phagocytosis, regulation of cellular
growth, metabolism of xenobiotics) [15]. When generated
excessively or when antioxidant function is disturbed,
ROS can be cytotoxic through the oxidation of biomole-
cules (e.g., membranes, enzymes, carbohydrates, DNA).
ROS have been implicated in cancer initiation, promotion
and progression [16,17]. Cancer cells, presumably
through mitochondria dysfunction and increased meta-
bolism, generate a relatively high level of ROS and modu-
lation of cellular ROS has been suggested as a strategy to
selectively target cancer cells over normal cells [18,19].
Iron chelators suggested as potential anti-tumor
agents include deferoxamine (DFO) [20], deferiprone
and deferasirox [21], tachpyridine [22], triapine [23] and
O-trensox [24]. Iron is an essential component of many
biological molecules including hemoglobin, myoglobin,
ribonucleotide reductase (RR), cyclooxygenases, lipoxy-
genases, iron-sulfur proteins and hydroxylating enzymes
[22,25]. An elevated level of iron has been linked to
tumor risk [26] and the growth of neoplastic cells due
to iron’s catalytic effect on the formation of hydroxyl
radicals and the suppression of host defense cell activity
[27]. Neoplastic cells display an elevated expression of
transferrin and its receptor as well as a high rate of iron
internalization thereby justifying the development of
chelating compounds for cancer therapy [28,29].
Accordingly, cancer cell death can be induced by deplet-
ing the intracellular iron pool as shown by H-ferritin
expression in ovarian cancer cells [30]. Targeting tumors
with chelating agents in an attempt to alter cellular iron
homeostasis or metabolism is a promising treatment
approach [31].
The objective of the present study was to investigate
the cytotoxic potential of 6- lipophilic aroylhydrazone
chelators (AHCs) in ovarian cancer cell lines. The pre-
sent report suggests that newly designed compound
HNTMB displays cytotoxic properties superior to other
AHCs and to iron-chelator deferoxamine (included as
control [20]). The mode of action in SKOV-3 ovarian
cancer cells relies on the generation of ROS, caspase
activation, Bcl-2 reduction, DNA degradation and G2/M
phase cell cycle block. HNTMB when complexed with
copper (I) or (II) but not with Fe(II) or (III) generates
ROS and is highly cytotoxic. In summary, HNTMB may
serve as a potential therapeutic drug and an alternative
to platinum drugs in the treatment of ovarian cancer.
Methods
Synthesis and Materials
Deferoxamine mesylate (DFO) was purchased from
Sigma-Aldrich (St. Louis, MO). AHC compounds
oVtBBH [32], HNtBBH [33], StBBH/206, HNTh2H/315
and HNI/311 [34,35] have been described previously. All
AHCs were synthesized as follows using the Schiff base
condensation method. Briefly, each aldehyde was com-
bined with an equimolar amount of the corresponding
hydrazide in ethanol, stirred and refluxed. The resultant
materials were collected by filtration to afford the desired
product and were further purified by re-crystallization
(HNI, StBBH and oVtBBH). The compounds were char-
acterized by 1H nuclear magnetic resonance spectroscopy
(1H NMR) and mass spectrometry. Salicylaldehyde-4-t-
butylbenzoyl hydrazone (StBBH/206): yield 92%. Analyti-
cal data; 1H NMR [dimethyl sulfoxide (DMSO)-d6, δ]
12.0 (1H), 11.3 (1H), 8.6 (1H), 7.9 (2H), 7.5 (3H), 7.3
(1H), 6.9 (2H), 1.3 (9H). FAB-MS m/z (nitrobenzyl alco-
hol/NaI matrix) calculated for C18H20N2O2, 296.15 [M
+],
found 319 [M+Na]+. 2-hydroxy-1-naphthylaldehyde-4-t-
butylbenzoyl hydrazone (HNtBBH): yield 71%. Analytical
data; 1H NMR (DMSO-d6, δ) 12.8 (1H), 12.1 (1H), 9.5
(1H), 8.2 (1H), 7.9 (4H), 7.6 (3H), 7.4 (1H), 7.2 (1H), 1.3
(9H). FAB-MS m/z (nitrobenzyl alcohol/NaI matrix) cal-
culated for C22H22N2O2, 346.2 [M
+], found 369.2 [M
+Na]+. 3-Methoxysalicylaldehyde-4-t-butylbenzoyl hydra-
zone (oVtBBH): yield 69%. Analytical data; 1H NMR
(DMSO-d6, δ;) 12.0 (1H), 11.09 (1H), 8.6 (1H), 7.9 (2H),
7.5 (2H), 7.1 (1H), 7.0 (1H), 6.8 (1H), 3.8 (3H) 1.3 (9H).
FAB-MS m/z (nitrobenzyl alcohol/NaI matrix) calculated
for C19H22N2O3, 326.2 [M
+], found 349.1 [M+Na]+. 2-
hydroxy-1-naphthylaldehyde 3,4,5-trimethoxy-benzoylhy-
drazone (HNTMB): yield 67%. 1H NMR (DMSO-d6, δ)
12.8 (1H), 12.1 (1H), 9.5 (1H), 8.3 (1H), 7.9 (2H), 7.6
(1H), 7.3 (4H), 3.9 (6H), 3.8 (3H). FAB-MS m/z (nitro-
benzyl alcohol/NaI matrix) calculated for C21H20N2O5,
380.14 [M+], found 403.3 [M+Na]+. 2-hydroxy-1-
naphthylaldehyde isonicotinoyl hydrazone (HNI/311):
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58% yielded. Analytical data; 1H NMR (DMSO-d6, δ) 12.5
(1H), 12.4 (1H), 9.5 (1H), 8.8 (2H), 8.3 (1H) 7.9 (4H) 7.6
(1H) 7.4 (1H) 7.2 (1H). ES-MS calcd for C17H13N3O2,
291.1 [M+], found 292.3 [M+1]+. 2-Hydroxy-1-naphthy-
laldehyde 2-thiophenecarboxy hydrazone (HNTh2H/
315): yield 59.2%. Analytical data; 1H NMR (DMSO-d6,
δ) 12.6 (1H), 12.2 (1H), 9.4 (1H), 8.3 (1H), 7.9 (4H), 7.6
(1H), 7.4 (1H), 7.2 (2H). FAB-MS m/z (nitrobenzyl alco-
hol/NaI matrix) calculated for C16H12N2O2S, 296.06 [M
+], found 319.2 [M+Na]+.
Cell culture and cell viability assay
SKOV-3 and OVCAR-3 (human ovarian adenocarcino-
mas) were purchased from ATCC (Manassas, VA). Cells
were grown in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with bovine calf serum or fetal
calf serum (10% for SKOV-3, 20% for OVCAR-3).
NUTU-19 rat epithelial ovarian cancer cells derived
from Fischer 344 rats [36], a gift from Dr. G. Scott Rose
(Section of Gynecologic Oncology, Cleveland Clinic
Foundation, Cleveland, OH 44195, USA), were cultured
in RPMI 1640 supplemented with 10% fetal bovine
serum. Cells were cultured in the presence of 100 unit/
ml penicillin G and streptomycin at 37°C with 5% of
CO2 in a humidified incubator. Viability of cell lines
before and after drug treatment was determined by the
CellTiter 96® AQueous One Solution Assay (Promega
Corp, Madison, WI) following the manufacturer’s
recommendations with suitable modifications. This col-
orimetric assay is based on the ability of mitochondria
to reduce a substrate [MTS, 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] into a soluble formazan product quantified
by measuring the absorbance at 490 nm. The resulting
OD is directly proportional to the number of living cells
[37]. Briefly, cells were seeded into a 96-well microtiter
plate at 5,000 cells/100 μl per well in complete medium,
allowed to attach at 37°C with 5% of CO2, in a humidi-
fied incubator and cells were treated with complete
medium containing drugs originally dissolved in
dimethyl sulfoxide (DMSO). Concentrations of the
drugs are indicated for the respective experiment; the
final concentration of the vehicle did not exceed more
than 0.2% (v/v). To determine the cytotoxicity when
complexed with Fe(II), Fe(III), Cu(I) or Cu(II), HNTMB
was combined with the respective metal salt (FeCl2,
FeCl3, CuCl or CuCl2) (5 mM stock solutions in
DMSO). Complexes were formed by combining stock
solutions of salts and chelator to 1000× the desired final
assay concentration in DMSO, incubated at 37°C for 30
min before further dilution in complete medium for cell
treatment. During the last 4 h of incubation at 37°C in a
cell culture incubator, the MTS reagent was added at a
1:10 dilution to the medium. After the treatment period
(as indicated) absorbance was measured at 490 nm in
an ELISA plate reader (Thermo Labsystems, Waltham,
MA). Experiments were performed in triplicates; data
are expressed as the mean of the triplicate determina-
tions (X ± SD) of a representative experiment in % of
absorbance by samples with untreated cells [=100%].
NCI 60 cancer cell line assay
HNTMB was screened through the National Cancer
Institute (NCI) Developmental Therapeutics Program
(DTP) 60 human cancer cell line panel under the In
Vitro Cell Line screening Project (IVCLSP). Briefly, cells
(5,000 to 40,000 cells/well depending on the cell line
studied) were inoculated into 96 well microtiter plates
in 100 μl complete RPMI1640 medium (5% FBS and 2
mM L-glutamine) and incubated 24 h prior to addition
of HNTMB. HNTMB was added and the plates were
incubated at 37°C, 5% CO2, 95% air, and 100% relative
humidity for an additional 48 h. Upon the addition of
50 μl of cold TCA (10% TCA) the assay was terminated
and incubated for 60 min at 4°C to fix the cells. The
supernatant was discarded, and the plates washed five
times with water and air dried. Sulforhodamine B solu-
tion (100 μl) at 0.4% (v/v) in 1% acetic acid was added
to each well, and plates incubated for 10 min at room
temperature. After staining, unbound dye was removed
by washing five times with 1% acetic acid and the plates
were air dried. Bound stain was subsequently solubilized
with 10 mM trizma base, and the absorbance was read
on an automated plate reader at a wavelength of 515
nm. Using absorbance measurements [time zero (Tz),
control growth (C), and test growth in the presence of
drug at the drug concentration (Ti)], the percentage
growth was calculated. Percentage growth inhibition was
calculated as: [(Ti-Tz)/(C-Tz)] × 100 for concentrations
for which Ti >/= Tz, [(Ti-Tz)/Tz] × 100 for concentra-
tions for which Ti < Tz.
Morphological Studies
To assess morphological changes and chromatin con-
densation of SKOV-3 cells undergoing apoptosis follow-
ing treatment with an iron-chelator, cells were stained
with 4’,6-diamidino-2-phenylindole (DAPI) and exam-
ined by fluorescence microscopy. Cells were seeded into
compartments of 8-well Lab-Tek® II chamber slide
(Nalge Nunc International, Naperville, IL), allowed to
attach onto the slide and deprived of serum for 18 h
prior to the incubation with 0.2 μM HNTMB for 24 h.
The cells were then washed with 1×PBS with Calcium/
Magnesium (Invitrogen, Carlsbad, CA), fixed and per-
meablized by 2% paraformaldehyde solution with 0.2%
Trition-X-100 in 1×PBS for 30 min at room tempera-
ture. The fixed cells were washed with 1×PBS. After
removal of the upper chamber and silicone lining the
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cells were stained and mounted at room temperature
with Vectashield® Mounting Medium for Fluorescence
with DAPI (Vector Laboratories). Once the excess
amount of mounting medium was removed, the slide
was examined under the fluorescence microscope
(ECLIPSE TE 2000-E, Nikon Inc.).
TUNEL Assay
DNA fragmentation was detected using the DeadEndTM
Fluorometric TUNEL System assay (Promega, Madison,
WI) according to the manufacturer’s recommendations.
Cells (4 × 105/well) were seeded into 8-well Lab-Tek® 11
chamber slide (Nalge Nunc International, Naperville,
IL), treated with 0.2 μM HNTMB and the assay carried
out as described previously [38]. Fluorescence of apop-
totic cells (green; labeling of DNA nicks by fluorescein-
12-dUTP) and of chromatin (red; staining of chromatin
with propidium iodide) was detected by fluorescence
microscopy with an inverted microscope (Nikon Eclipse
TE2000-E) and a 20× objective. Four randomly chosen
microscopic fields were captured.
Western Blot Analysis
SKOV-3 cells (1.5 × 106 per dish) were seeded into 100
mm cell culture dishes allowed to attach overnight and
serum-deprived for 18 h prior to the treatment under
the condition as mentioned. Following treatment, cells
were processed as described previously [39] in Cell
Extraction Buffer (BioSource International, Inc., CA.)
supplemented with protease inhibitor cocktail and phe-
nylmethylsulfonyl fluoride (Sigma-Aldrich) according to
the manufacturers’ recommendations. Lysates were
incubated at 4°C for 30 min, sonicated (10 pulses 5 sec),
centrifuged at 14,0000 g for 10 min, and the protein
concentration of the supernatant quantified (BioRad
protein estimation kit, Hercules, CA). Protein electro-
phoresis was performed by using the NuPAGE® Gel sys-
tem (Invitrogen, Carlsbad, CA). Briefly, each lysate
sample was mixed with LDS sample buffer and sample
reducing buffer, incubated at 70°C for 10 min, loaded
(50 μg/sample) and separated by using Xcell Sure-
LockTM mini-cell electrophoresis system (Invitrogen,
Carlsbad, CA) on NuPAGE® 4-12% Tris-Bis Gel in
NuPAGE® MES SDS running buffer, transferred onto a
PVDF membrane, blocked with 5% nonfat dry milk in
PBS-Tween and probed against various primary antibo-
dies (dilution 1:1000, all from rabbit: PARP #9541, XIAP
#2045, caspase-3 #9661, caspase-7 #9491, caspase-9
#9501 (Asp330/37 kD fragment) or #9505 (Asp315/35
kD fragment), caspase-8 #9496, Bcl-xL #2762, Bid
#2002; Cell Signaling Technologies, Danvers, MA), Bcl-2
#551107 (BD Biosciences, San Jose, CA) or mouse beta-
actin #sc-47778 or GAPDH #sc-47724 antibody (Santa-
cruz Biotechnology, Santa Cruz, CA; dilution 1:2000).
The bands were visualized using horseradish peroxidase-
conjugated secondary antibody (Amersham-Pharmacia
Biotech, Piscataway, NJ), followed by enhanced chemilu-
minescence (Upstate, Waltham, MA) and documented
by autoradiography (F-Bx810 Film, Phenix, Hayward,
CA).
Cell cycle analysis
Cell cycle analysis and quantification of apoptosis was
carried out by flow cytometry. SKOV-3 (1.0 × 106) cells
were seeded into 100 mm cell culture dishes, allowed to
attach overnight and treated for 48 h. At the end of the
incubation period, cells were scraped off and transferred
into 15 mL polypropylene centrifuge tubes along with the
medium. Culture dishes were then washed once with 1×
PBS, combined in the same tube. After centrifugation
(250 g, 5 min) cells were fixed by adding the ice-cold 70%
ethanol solution gradually. The cells were stained in the
buffer containing propidium iodide (100 μg/ml), sodium
citrate (1 mg/ml) and Triton-X-100 (3 μL/ml) for 30 min
at 37°C in the dark. Data was acquired on a BD FACSort
flow cytometer using CellQuest software (BD Immunocy-
tometry Systems, San Jose, CA) and analyzed by using
ModFit LT software (Verity Software House, Inc., Top-
sham, ME). Ten thousand events were analyzed for each
sample. Appropriate gating was used to select the single
cell population SKOV-3 cells. The same gate was used on
all samples, ensuring that measurements were conducted
on a standardized cell population.
Detection of intracellular Reactive Oxygen Species (ROS)
Detection of intracellular ROS after SKOV-3 treatment
with non-complexed or complexed HNTMB (see Viabi-
lity assay section) was measured by flow cytometry
using carboxy-H2DCFDA dye (Invitrogen, Carlsbad,
CA) as a probe. Carboxy-H2DCFDA is the acetylated
form of a reduced fluorescein derivative that is cell-
permeable and non-fluorescent. Once the acetate groups
are cleaved by intracellular esterase activities, this com-
pound becomes charged and better retained within the
cell as compared to its lipophilic parent compound. In
the presence of a cellular oxidant, the compound is oxi-
dized and produces green-fluorescence that is detected
by flow cytometry. This dye detects the following ROS:
hydrogen peroxide (H2O2), hydroxyl radical (HO
•), and
peroxyl radical (ROO•). SKOV-3 (1.0 × 106) cells were
seeded into 100 mm cell culture dishes, allowed to
attach overnight and treated under the condition as
indicated. Following treatment, cells were further incu-
bated with 25 μM of carboxy-H2DCFDA for 30 min at
37°C with 5% CO2 in a humidified incubator. Cells were
harvested by trypsinization, centrifuged, then washed
once with PBS and suspended in PBS. Data was
acquired on a BD FACSort flow cytometer using
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CellQuest software (BD Immunocytometry Systems, San
Jose, CA) and analyzed by using ModFit LT software
(Verity Software House, Inc., Topsham, ME).
Data Analysis
Mean and standard deviation (SD) were calculated. Mean
differences were determined by Student’s t-test or deter-
mined by one-way ANOVA, using the Newman-Keuls
test to account for multiple comparisons in post hoc ana-
lyses, except were indicated. Software used for these ana-
lyses was STATA 9.0 (StataCorp, College Station, TX.
Results
Cytotoxic effect of aroylhydrazone chelators on ovarian
cancer cell lines
In an initial approach to analyze the potential of a vari-
ety of lipophilic iron-chelators of the AHC class as anti-
cancer drugs we performed viability assays employing
two human platinum-resistant ovarian cancer cell lines
(SKOV-3 and OVCAR-3) a rat ovarian cancer cell line
(NUTU-19). The cytotoxic activity of each compound
was measured by a colorimetric MTS assay (see Material
and Methods), based on the reduction of a tetrazolium
compound in active cell metabolism. DFO was included
as a control compound. After cell treatment for 72 h all
six AHC tested showed more potent cytotoxic effects
(Fig. 1) than DFO (IC50 of 25 μM for SKOV-3, 12 μM
for OVCAR-3 and NUTU-19) in all tested ovarian can-
cer cell lines. Novel compound HNTMB (Fig. 2), dis-
played superior cytotoxicity (72 h treatment, IC50 of 200
nM for SKOV-3, 400 nM for OVCAR-3 and NUTU-19)
(Fig. 1) when compared to all other 5 AHC tested
(oVtBBH, HNtBBH, StBBH/206, HNTh2H/315, HNI/
311) which were highly cytotoxic only at higher drug
concentrations with IC50 values between 800 nM and 6
μM depending on the cell line or compound studied.
HNTMB displays differential effects on the growth of
various human cancer cell lines
The NCI-DTP performed a screen on HNTMB as a
growth suppressor against a panel of 60 human cancer
cell lines. The HNTMB concentrations representing 50%
growth inhibition (GI50, Fig. 3A) were determined by
using the dose-response growth curves of OVCAR ovar-
ian cancer cell lines and other cancer cells (colon, lung,
melanoma, leukemia, renal, prostate, central nervous sys-
tem) against HNTMB concentrations ranging from 10
nM to 100 μM) (Fig. 3A, B). HNTMB exhibited growth
inhibitory effects against all cell lines tested with remark-
able differences in specificity in a 240 fold range of GI50
values (between 10 nM and 2.4 μM depending on the cell
line studied). HCC-2998 (colon) and MDA-MB-468
(breast) cancer cell lines appeared to be the most sensi-
tive toward the HNTMB treatments (GI50 ≤ 10 nM).
Relatively strong growth inhibitory effects (with GI50
values less than 50 nM) of HNTMB were observed in 5
out of 6 leukemia cells (CCRF-CEM, HL-60(TB), K-562,
RPMI-8226 and SR), 3 out of 9 non-small cell lung can-
cer cells (HOP-62, NCI-H460 and NCI-H522), 6 out of 7
colon cancer cells (HCC-2998, HCT-116, HCT-15,
HT29, KM12 and SW-620), 2 out of 6 CNS cancer cells
(SF-295 and SF-539), 4 out of 8 renal cancer cells (786-0,
A498, CAKI-1 and RXF 393), 2 out of 2 prostate cancer
(PC-3 and DU-145) and 5 out of 8 breast cancer cells
(MCF-7, NCI/ADR-RES, HS 578T, MDA-MB-435 and
MDA-MB-468). Among ovarian cancer OVCAR-3 (GI50
= 38 nM) displayed the highest sensitivity when com-
pared to OVCAR-4, -5, and -8 (Fig. 3C).
Morphological changes, DNA fragmentation in SKOV-3
ovarian cancer cells after HNTMB treatment
Cells undergoing apoptosis display characteristic
changes in their morphology including plasma mem-
brane blebbing, cell shrinkage, condensation and frag-
mentation of the nucleus and the formation of apoptotic
bodies. In order to distinguish whether cell death in
ovarian cancer cells upon HNTMB treatment is due to
apoptosis, we first examined the morphologic changes
of SKOV-3 cells after drug treatment. Nuclear staining
using 4’,6-diamidino-2-phenylindole (DAPI), a fluores-
cent DNA-binding dye, revealed that ~40% of SKOV-3
cells treated with HNTMB exhibited apparent nucleus
condensation and fragmentation upon HNTMB treat-
ment (0.2 μM, 24 h) whereas the untreated control cells
were not affected (Fig. 4A).
Another hallmark feature of cells undergoing apopto-
sis is often characterized by chromatin fragmentation e.
g. cleavage of genomic DNA to 180-200 bp fragments.
This event within individual cells can be analyzed by
terminal deoxynucleotidyl transferase-mediated dUTP
(conjugated to fluorescein) nick end labeling (TUNEL)
[40]. SKOV-3 cells were treated with HNTMB and DNA
fragmentation was visualized by fluorescence microscopy
(Fig. 4B). To identify the entire population of SKOV-3
cells, the nuclei of cells were counterstained with propi-
dium iodide (PI), a red fluorescence DNA intercalating
dye. Treatment of SKOV-3 cells with 0.2 μM HNTMB
for 24 h revealed an apoptotic population of ~40% of
cells with TUNEL positive nuclei (red/green channel
overlay resulting in yellow color) whereas the untreated
control cells were TUNEL-negative (Fig 4B).
Induction of apoptosis in ovarian cancer cells after HTMB
treatment
To define the cellular response of SKOV-3 cells upon
HNTMB treatment we analyzed the activation of apop-
totic markers by immunoblotting. Following HNTMB
treatment for 24 h Western blotting confirmed the
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Figure 1 Cytotoxic effect of aroylhydrazone chelators (AHC) in comparison to DFO in ovarian cancer cells. The cytotoxicity of chelators
on human ovarian cancer cells (SKOV-3, OVCAR-3) and a rat ovarian cancer cells (NUTU-19) was evaluated by using the MTS viability assay as
described (Materials and Methods). The cells were treated for 72 h with varying concentrations of various AHCs or DFO as control. HNTMB
displayed the highest cytotoxicity (IC50 = 0.2-0.8 μM depending on the cell line studied). Experiments were performed in triplicates; data are
expressed as the mean of the triplicate determinations (X ± SD) of a representative experiment in % cell viability of untreated cells [100%].
Figure 2 Structure of HNTMB. Synthetic scheme (Schiff base condensation method; for synthesis details see Materials and Methods) and
structure of HNTMB.
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Figure 3 Cell growth after HNTMB treatment in NCI60 cancer cell line screen. Cells were treated in 96 well plates with HNTMB or vehicle
and cell growth of the TCA fixed treated and untreated cells assessed (Material and Methods) after 48 h with Sulphorhodamine-B (SRB) solution
and absorbance read at 515 nm.
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activation of effector caspase-3, -7 and inactivation of
PARP-1 (involved in DNA repair) in SKOV-3 cells (Fig.
5A). The cleavage of PARP is thought to represent the
irreversible stage of cellular process in apoptosis events.
In addition the expression of pro-survival marker XIAP,
a direct inhibitor of executioner caspases such as cas-
pase-3, was gradually down-regulated within 9 to 48 h
following the HNTMB treatment (Fig. 5A).
Moreover, it was apparent that HNTMB induced both
major signaling pathways (intrinsic, extrinsic) described
for programmed cell death. A prominent marker for the
extrinsic pathway is activation of caspase-8 which
occurred following SKOV-3 treatment with HNTMB for
24 h (Fig. 5A). Features of the intrinsic pathway include
the activation of pro-apoptotic members of the Bcl-2
family and/or down-regulation of anti-apoptotic Bcl-2
family members and cleavage/activation of caspase-9
which also occurred in SKOV-3 following 24 h of
HNTMB treatment (Fig. 5A). Caspase-9 was activated
by a feedback mechanism through cleavage (at Asp330)
via caspase-3 yielding a large fragment, p37, (Fig. 5A)
and through apoptosome-dependent self-cleavage (at
Asp315) yielding fragment p35 (data not shown). Inter-
estingly, down-regulation of anti-apoptotic Bcl-2 but not
Bcl-xL was observed (Fig. 5B). In addition, no change in
the expression of full-length Bid (22 kD) or truncated-
Bid (also known to trigger mitochondrial signaling) was
observed (Fig. 5B).
HNTMB treatment induces SKOV-3 cell cycle arrest in G2/
M phase
As described in the previous sections, HNTMB is a
cytotoxic agent which activates apoptotic processes in
SKOV-3 ovarian cancer cells. To investigate if HNTMB
Figure 4 Morphology changes and DNA fragmentation in ovarian cancer cells after HNTMB treatment. (A) Morphological changes
following HNTMB treatment. SKOV-3 cells were treated for 24 h with 0.2 μM HNTMB, fixed and stained with 4’-6-Diamidino-2-Phenylindole
(DAPI) as described (Materials and Methods) before mounting. Microscopy was carried out (Nikon Eclipse TE2000-E inverted microscope, 20×
objective) and representative images were taken. Bar = 10 μm. (B) TUNEL assay. SKOV-3 cells were treated with 0.2 μM of HNTMB for 24 h.
Labeling of DNA nicks with fluorescein-12-dUTP and chromatin counterstaining with propidium iodide was carried out as described (Materials
and Methods). Representative images were taken, apoptotic stain (FL-dUTP, green) and nuclear stain (Pi, red) overlaid; TUNEL positive nuclei due
to DNA fragmentation appear as yellow areas. Bar = 10 μm.
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affects the proliferation of SKOV-3 cells (particularly at
drug concentrations when viability is only partially
reduced) we analyzed the cell cycle distribution of
SKOV-3 cells in response to HNTMB treatment by
FACS.
While only 4.4% of untreated cells were present in the
G2/M sub-population, HNTMB treatment for 48 h led
to a dose-dependent G2/M phase arrest (Fig. 6A) with
23.8% cells (at 0.3 μM drug concentration) and 67.3%
cells (at 0.6 μM) in G2/M (Fig. 6B). Accordingly, the
cell sub-population in G0/G1 phase, when compared to
untreated cells (78.7%), was reduced to 42.7% (0.3 μM
HNTMB) and 8.2% (0.6 μM HNTMB), respectively. In
addition, FACS analysis after HNTMB treatment
revealed an increase in the count of apoptotic sub-
diploidal/2n cells (sub-G0/G1, Fig. 6B) in a dose-depen-
dent manner. Treatment of this unsynchronized cell cul-
ture led to a delayed progression of cells through S-
phase (16.9% in untreated SKOV-3) which was apparent
at 0.3 μM HNTMB (33.5% in S-phase). At the highly
cytotoxic concentration of 0.6 μM drug we observed a
loss of cells in culture due to cell shrinkage and
disintegration, an increase of apoptotic sub-diploidal/2n
cells (34.3%) while 24.5% of the cells were in S-phase.
HNTMB/Copper complexes but not HNTMB/Iron
complexes mediate cytotoxicity and ROS generation
HNTMB as a chelator has the potential to bind various
trace metals present in human tissues, cancer, serum,
plasma and cell lines, such as iron, copper, zinc, magne-
sium, cadmium. In a viability assay we determined the
cytotoxicity of HNTMB when complexed with Fe(II), Fe
(III), Cu(I) or Cu(II). Complexes were formed by com-
bining stock solutions of HNTMB and respective metal
salts (FeCl2, FeCl3, CuCl or CuCl2) to 1000× the desired
final assay concentration in DMSO, followed by incuba-
tion at 37°C for 30 min before further dilution in com-
plete medium for cell treatment.
The IC50 following 48 h treatment of SKOV-3 with
non-complexed HNTMB is approximately 0.4 μM. Fig.
7A shows that at this drug concentration cell viability
was reduced to 54.8% of the untreated controls. Pre-
viously, in a publication on the chemotherapeutic activ-
ity of Salophene complexes we showed that Fe[III] alone
does not display significant cytotoxic effects in SKOV-3
Figure 5 Expression of apoptotic markers in SKOV-3 cells after HNTMB chelator treatment. SKOV-3 cells were treated with HMTNB (0, 0.2,
0.8 μM) for 9, 24 or 48 h. PAGE and Western blot analysis of cell lysates were carried out as described (Materials and Methods). A representative
experiment is shown. Immunoblotting was carried out with primary antibodies against PARP, caspase-3, caspase-7, caspase-8, caspase-9, Bcl-2,
Bid, and XIAP. As an internal standard for equal loading blots were probed with an anti-b-Actin antibody.
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cells at or below the concentrations of 60 μM, whereas
Cu[II] displays partial cytotoxicity (33% of cells) at a
concentration of 60 μM but not ≤30 μM [41]. Accord-
ingly, treatment of SKOV-3 cells with FeCl2, FeCl3,
CuCl or CuCl2 at concentrations of 1.6 μM did not
affect cell viability nor did 0.4 μM HNTMB when com-
plexed with Fe(II) or Fe(III). In contrast, 0.4 μM
HNTMB when complexed with Cu(I) or Cu(II) was
highly cytotoxic to the cells (Fig. 7A). When HNTMB
was chelated with Cu(II) (at 1000× the desired assay
concentration and prior to 1000 fold dilution in com-
plete medium for treatment), cell viability was reduced
2-fold (26.4%; Cu(II)/HNTMB 1.6/0.4 μM) as compared
to non-complexed HNTMB (54.8%). Using a Cu(I)/
HNTMB complex (1.6/0.4 μM) viability was reduced to
31.9%. When chelation was carried out in the presence
of Cu salts cytotoxicity was still higher (43.3% for Cu
(II)/HNTMB 0.8/0.4 μM and 40.7% for Cu(I)/HNTMB
1.6/0.4 μM) compared to non-complexed HNTMB.
These results indicated that (i) we efficiently achieved
HNTMB-metal complexation under the experimental
conditions described (Material and Methods), (ii)
HNTMB pre-chelated with iron did not exert cytotoxic
effects in SKOV-3 cells, (iii) no significant dissociation
of these pre-formed complexes occurred under our
experimental conditions because measured cytotoxicities
were, for example, less than [in the case of Fe (II or III)]
that for non-complexed HNTMB, and iv). Pre-Cu che-
lated HNTMB was more cytotoxic than non-complexed
HNTMB.
Next, we carried out HNTMB complex formation
under competing conditions for Fe and Cu-salts (Fig.
7B; group 1) prior to performing cell viability assays or
we combined pre-formed Fe/- and Cu/HNTMB com-
plexes and measured their effects in the viability assay
(Fig. 7B; group 2.). When Fe(II)- and Cu(II)-salts were
incubated together with HNTMB prior to treatment
(Fig. 7B, group 1), cell viability was reduced to 71.3%
(Fe(II)/Cu(II)/HNTMB) compared to 104.4% for Fe(II)/
HNTMB, 43.3% for Cu(II)/HNTMB and 54.8% for non-
complexed HNTMB (Fig. 7A). These data suggest that
HNTMB, under our experimental conditions, had a
similar affinity for Fe salts and Cu salts. Accordingly,
when Fe(III) and Cu(II) were incubated together with
HNTMB prior to treatment viability was reduced to
68.8% for Fe(III)/Cu(II)/HNTMB) compared to 96.9%
Figure 6 HNTMB causes G2-Phase cell cycle arrest in SKOV-3 cells. SKOV-3 cells were treated with 0.3 or 0.6 μM HNTMB for 48 h. Cell cycle
analysis of treated and untreated cells was carried out as described (Materials and Methods). Data were obtained by FACS analysis based on
propidium-iodide intercalation into cellular chromatin and are presented as (A) relative fluorescence intensity in a 2-dimensional FACS profile
(ModFit LT software; black lines = data line and model fit line of entire population; shaded areas = model components/subpopulations of G0/G1,
S, G2/M, apoptotic cells or as (B) a table. Standardized gating was used for all samples. Ten thousand events were analyzed for each sample.
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Figure 7 Effect of iron/HNTMB and copper/HNTMB complexes on viability, ROS generation, and induction of apoptosis. (A) Cytotoxicity
of HNTMB in SKOV-3 cells when complexed with Fe(II), Fe(III), Cu(I) or Cu(II) Complexes were formed by combining HNTMB and respective metal
salts to 1000× [0.4 mM HNTMB; 1.6 or 0.8 mM Fe(II), Fe(III), Cu(I) or Cu(II)] the assay concentration before addition (diluted 1:1000) to the cells (48
h treatment). As controls served cells left untreated, incubated with metal salts (1.6 μM) or non-complexed HNTMB (at IC50 concentration, 0.4
μM). Data are expressed as mean of triplicate determinations (X ± SD) in % cell viability of untreated cells [100%]. (B) Combinational effect of
HNTMB iron- and copper-complexes on cell viability in SKOV-3 cells. Group 1: HNTMB complex formation was performed under competing
conditions for Fe and Cu-chelation at 1000× the desired assay concentration before addition of this mixture (diluted 1:1000) to the cells (48 h
treatment). Group 2: Stock solutions (1000×) of pre-formed complexes of Fe(II) or Fe(III)/- and Cu(II)/HNTNB were individually diluted before
simultaneous addition to the cells (48 h treatment). (C) Detection of intracellular ROS in SKOV-3 cells Generation of ROS following treatment with
non-complexed or complexed HNTMB was measured by flow cytometry. Data are presented as relative-fluorescence-intensity in a 2-dimensional
FACS profile (standardized gating; 10.000 events). (D) Effect of HNTMB complexation with Fe(III) or Cu(II) on the viability of various ovarian cancer
cell lines SKOV-3, OVCAR-3 or NUTU-19 cells were treated with 0.4 μM non-complexed or complexed (Cu(II)-upper panel; Fe(III)-lower panel)
HNTMB for 48 h and the assay carried out. (E) Effect of HNTMB complexation with Fe(III) or Cu(II) on expression of apoptotic markers in various
ovarian cancer cell lines SKOV-3, OVCAR-3 or NUTU-19 cells were treated with 0.4 μM non-complexed or complexed HNTMB for 48 h. Western
blot analysis of cell lysates was carried with primary antibodies against PARP-1, caspase-7 and GAPDH (control).
Kim et al. BMC Cancer 2010, 10:72
http://www.biomedcentral.com/1471-2407/10/72
Page 11 of 18
for Fe(III)/HNTMB, 43.3% for Cu(II)/HNTMB and
54.8% for non-complexed HNTMB (Fig. 7A).
When Fe or Cu complexes were pre-formed (0.8 μM
metal, 0.4 μM HNTMB) and added individually to the
cells (Fig. 7B, group 2), cell viability was 40.9% for Fe
(III)/HNTMB+Cu(II)/HNTMB and 44.8% for Fe(II)/
HNTMB+Cu(II)/HNTMB) instead of 43.3% viability
when the same concentration of Cu(II)/HNTMB alone
was used (Fig. 7B, arrow). This suggested that the cyto-
toxicity exerted by a copper/HNTMB complex was not
altered and that no additional cytotoxic effect through
co-treatment with an iron/HNTMB complex was
achieved.
One potential strategy suggested to treat cancer is to
generate an excess amount of ROS in tumor tissue to
induce necrosis and/or apoptosis. We determined if
SKOV-3 following treatment with non-complexed
HNTMB or Cu/Fe complexed-HNTMB lead to the gen-
eration of ROS. These species were detected via Car-
boxy-H2DCFDA, which is a fluorescein derivative that is
cell-permeable and non-fluorescent. In the presence of a
cellular oxidant, the molecule is oxidized and produces
green-fluorescence that is detected by flow cytometry. As
shown in Fig. 7C, ROS generation in SKOV-3 cells
remained unchanged as compared to untreated controls
when either Fe(III)/HNTMB complex (0.8/0.4 μM) or
FeCl3 and CuCl2 metal salts (0.8 μM) were used. How-
ever, ROS generation increased (shift in relative fluores-
cence intensity, Fig. 7C) following treatment of cells for
20 h with either 0.4 μM non-complexed HNTMB (upper
panel) or Cu(II)/HNTMB (0.8/0.4 μM; lower panel)
which correlated with a reduction in cell viability by
these compounds at the same concentration (Fig. 7A).
To rule out that the effects of HNTMB complexation
are cell type specific we compared the cytotoxic effects
(Fig. 7D) and induction of apoptotic markers (Fig. 7E)
by HNTMB when complexed with Fe(III) or Cu(II) in
three different ovarian cancer cell lines.
Human platinum resistant OVCAR-3 cells as well as
rat NUTU-19 displayed a similar response profile as
SKOV-3 and treatment of these cell lines with CuCl2 at
concentrations of 0.8 μM did not affect cell viability. In
contrast, 0.4 μM HNTMB when complexed with Cu(II)
was highly cytotoxic to the cells and exceeded toxicity
of non-complexed HNTMB (Fig. 7D, top panel).
Remarkably, complexation of HNTMB with Fe(III) fully
prevented cytotoxicity of the compound. The viability of
SKOV-3, OVCAR-3 and NUTU-19 compared to that of
untreated controls or cells treated with the respective Fe
(III) salt (Fig. 7D, bottom panel).
Following HNTMB treatment Western blotting con-
firmed the activation of effector caspase-7 and inactiva-
tion of PARP-1 (involved in DNA repair) in all three
cell lines by 0.4 μM of either non-complexed HNTMB
or when complexed with Cu(II) (Fig. 7E). Apoptosis was
not induced through HNTMB when complexed with Fe
(III) and expression levels of activated caspase-7 and
inactivated PARP-1 were similar to the controls
(untreated cells or cells treated with FeCl3 or CuCl2)
(Fig. 7E). Apoptosis was induced more rapidly by the
copper-complex as compared to treatment with non-
complexed HNTMB with a higher number of cells
showing degradation (data not shown). In line with the
kinetic study on the expression of apoptotic markers
peaking at 24 h (Fig. 5) activation of caspase-7 or inacti-
vation of PARP-1 at 48 h treatment with Cu(II)/
HNTMB when compared to treatment with non-com-
plexed HNTMB was past the peak and less pronounced.
However, the 48 h incubation was chosen to perform
the Western Blotting analysis (Fig. 7E) in conjunction
with our standardized Viability assay (48 h incubation;
Fig. 7A, B, D) and ROS detection assay (Fig. 7C) all
reveal that complexation of HNTMB with copper but
not with iron results in a potent drug to treat ovarian
cancer cells.
Discussion
Chelators in cancer treatment
A low overall survival for advanced stages of ovarian
cancer is related to the appearance of drug resistance to
standard agents, notably organometallic platinum com-
pounds. Research has been directed at the discovery of
non-platinum chemotherapeutics with increased activity
and response rates and among them chelating drugs and
chelator metal complexes [7,41-44]. In addition, the effi-
cacy of current anti-cancer drugs may be increased by
combinational treatment with chelating drugs which
have been shown to affect the metabolism and toxicity
of anti-cancer compounds such as adriamycin, mitozan-
trone, bleomycin and hydroxyurea (HU) [7].
The objective of the present study was to investigate
the potential of six different lipophilic aroylhydrazone
chelators (AHC) including novel compound HNTMB as
anti-tumor drugs and to analyze modes of action leading
to cell death of ovarian cancer cells following HNTNB
treatment. As a model system we choose OVCAR-3 cells
resistant to clinically relevant concentrations of adriamy-
cin, melphalan and cisplatin and SKOV-3 cells resistant
to several cytotoxic drugs including cisplatin and adria-
mycin (see ATCC, Manassas, VA; http://www.atcc.org).
To set the stage for potential future in vivo experiments
using chelators in a syngenic rat tumor model [41] we
included rat ovarian NUTU-19 cancer cell line in a
screen for cytotoxicity by the various AHC tested here.
Efficacy of aroylhydrazone chelators in cancer cells
Previous work showed that AHCs (often referred to as
iron-chelators due to initial studies on high Fe chelation
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efficacy in cell lines and in vivo models) [45] exert anti-
proliferative and/or cytotoxic effects in neoplastic cells
including cell lines derived from bladder carcinoma, rat
hepatoma, T-cell leukemia, neuroblastoma, melanoma
and leukemia [34,35,45-47]. To date no studies on the
effect of AHC compounds in ovarian cancer models,
neither in vitro nor in vivo, have been published, and
their mechanism of action leading to cell death remains
unknown.
The present study shows that novel compound
HNTMB in its cytotoxic capacity (IC50 between 200-400
nM depending on the ovarian cancer cell line) is super-
ior to other AHC compounds (oVtBBH, HNtBBH,
StBBH/206, HNTh2H/315 and HNI/311 and HNTMB)
(IC50 0.8-6 μM) as well as to deferoxamine (DFO) (IC50
12-25 μM) which was included as a reference. StBBH/
206, HNTh2H/315 and HNI/311 in previous studies dis-
played anti-proliferative effects in neuroblastoma cell
lines (IC50 = 0.2-1.2 μM), melanoma cells (IC50 0.8-1.0
μM) and leukemia cells (IC50 0.4-1.3 μM) [34,35]. Two
of the three AHC (HNTh2H/315 and HNI/311) and
HNTMB possess a 2-hydroxy-1-naphthylaldehyde moi-
ety. The high lipophilicity of this aldehydic moiety when
compared to AHC compounds with a less lipophilic pyr-
idoxal or salicylaldehyde group is correlated to increased
anti-proliferative effects [34] and likely contributes to
the effectiveness of the novel HNTMB studied here.
HNTMB, apart from a hydroxy-1-naphthylaldehyde moi-
ety and unlike the other structurally-related AHCs stu-
died here (HNI/311, HNTh2H/315, HNtBBH), possesses
a trimethoxybenzene moiety, which is found in a large
number of biologically active compounds, including
anti-cancer drugs such as combretastatin. The tri-
methoxybenzene moiety in HNTMB may be associated
with the further improvement of its cytotoxicity in com-
parison to the structurally-related chelators without
such a functional group. However, further studies must
be conducted to prove whether this moiety is directly
responsible for the high degree of cytotoxicity produced
by HNTMB. The control compound DFO, structurally
unrelated to AHCs, is a naturally occurring hexadentate
iron-chelator that has been used as a therapeutic agent
against ovarian [20] and other cancer cells [48-53].
However, the hydrophilic property of DFO limits its
membrane-permeability and efficacy to target the intra-
cellular trace metal pool including iron [54] or affect
other intracellular processes. In contrast to DFO, com-
pounds such as HNTMB display a greater potency
because of their better membrane-permeability profiles.
The observation to cytotoxic effects of HNTMB on
SKOV-3, OVCAR-3 and NUTU-19 ovarian cancer cells
led to a screen performed by the NCI-DTP against a
panel of cell lines http://dtp.nci.nih.gov/screening.html
derived from human tumors of different origin. It became
apparent that HNTMB displayed potent cell line-specific
but not tumor type-specific cytotoxicity with GI50 values
in a 240-fold range (between 10 nM and 2.4 μM depend-
ing on the cell line studied). Thus, cell death, depending
on the target tumor or cancer cell line, can be induced by
HNTMB at concentrations in the nanomolar range. At
these concentrations AHCs may not exert their effects by
critical depletion of the pool of intracellular iron but by
binding to other trace metals such as copper (see discus-
sion below). In vivo experiments have shown that effec-
tive treatment of tumors with related thiosemicarbazone
Dp44mT, which reduced growth in melanoma xenografts
in nude mice by 92%, required low doses that did not
cause iron depletion [55]. It is noteworthy that no direct
correlation between the anti-proliferative activity of
AHCs with their abilities to prevent iron-uptake or mobi-
lization in neuroblastoma cells was reported [34] suggest-
ing that interference with iron metabolism may not be
responsible for the effect of AHCs on cell viability. Early
studies examined the use of copper complexes of aroyl-
hydrazone derivatives as therapeutic agents; Cu(II) com-
plexation of SBH not only increased the compounds
cytotoxicity but administration of this complex in mice
was well tolerated [46]. The present study revealed that
HNTMB at 400 nM when complexed with Cu(I) or Cu
(II) displayed a high cytotoxicity correlated with massive
generation of ROS. In contrast, HNTMB complexed with
Fe(II) or Fe(III) lost its cytotoxicity and did not alter
basal levels of ROS in SKOV-3 cells. Non-complexed
HNTMB displayed partial cytotoxicity and by binding to
various trace metals is likely to disturb a multitude of
functions important for cell proliferation and survival.
HNTMB, as a tridentate coordinating ligand, has the
ability to bind copper or iron in a stochiometric ratio of
1:1. Its IC50 determined for ovarian cancer cell lines is
200-400 nM (75-150 μg/L) and the assay concentration
of non-complexed HNTMB that we used was 150 μg/L
which is a fraction of the total iron or copper content of
cells. Ovarian cancer tissues contain 0.3-0.7 mg/kg cop-
per and 15-17 mg/kg iron content [10]. By binding intra-
cellular copper HNTMB can create a toxic ROS-
generating complex, while intracellular iron-chelation by
HNTMB depending on its concentration may lead to a
variety of cellular consequences previously described for
aroylhydrazone chelators [31]. These include ribonucleo-
tide-reductase/RR inhibition, redox-activity leading to
the hydroxylation of benzoate and the degradation of
DNA in the presence of Fe(II) and H2O2, down-regula-
tion of cell cycle regulators, and activation of WAF (med-
iator of p53 tumor suppression) among other genes.
Response mechanism of cancer cells to HNTMB treatment
Through various experimental approaches the present
study suggests that the mode of action of HNTMB in
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SKOV-3 cells relies on a variety of inter-dependent pro-
cesses such as generation of ROS, DNA degradation,
induction of apoptosis, and arrest of cell cycle progres-
sion through G2/M phase. ROS are generated in SKOV-
3 when treated with a copper/HNTMB complex but not
when an iron/HNTMB complex was used. Thus, ROS
generation observed after treatment with non-com-
plexed HNTMB is, at least, partially due to the drug
binding intracellular copper (possibly by binding to
other trace metals with a similar result). Production of
ROS results in apoptosis and/or necrosis and can be
used for selective targeting of tumor cells which possess
higher oxidative stress level and display alteration of
antioxidant enzymes (catalase, SOD) as compared to
normal cells. Apparently, the Cu/HNTMB complex, as
suggested for other chemotherapeutic drugs, may be
used in oxidation therapy by elevating H2O2 and super-
oxide radical in tumor cells above the survival/death
threshold (see introduction) [17,56]. Even though excess
copper is known to be a potent oxidant causing the gen-
eration of ROS, we ruled out that unbound copper pre-
sent in the sample of the Cu/HNTMB complex could be
responsible for ROS generation. In controls, neither Cu
(I) nor Cu(II) alone, at concentrations of 1.6 μM,
resulted in cytotoxicity or ROS production during treat-
ment. Previously, we determined that treatment with
non-chelated copper does not affect the viability of ovar-
ian cancer cell at or below a concentration of 30 μM
[41]. Therefore, we suggest that future studies should
focus on the mechanistic responses of tumor cells to
treatment with copper/AHCs complexes in general and
specifically with a Cu/HNTMB complex in ovarian can-
cer models. The mechanism(s) by which the copper-
HNTMB complex generates elevated ROS levels remains
under investigation but may include targeting of cellular
thiol-containing anti-oxidant molecules such as glu-
tathione (GSH) as this has been shown for other copper
complexes such as CuNG [57]. Even upon treatment
with non-complexed HNTMB intracellular copper-che-
lation by HNTMB might selectively be used to cause
ROS-mediated cell death in certain tumors because a
higher copper level is apparent both in serum and
tumors of cancer patients including those suffering from
breast and ovarian cancer [8-10]. Reference values deter-
mined by Yaman et al. [10] showed an average copper
content in malignant ovarian tissue of 0.7 mg/kg copper
versus 0.3 mg/kg in benign ovarian tissue. Interestingly,
in these tissues the iron content for cancerous and non-
cancerous conditions is comparable (15-17 mg/kg) [10].
Thus, the iron/copper ratio decreases by a factor of 2
from benign to malignant ovarian tissues and may
represent a target for chelation therapy.
In the present study, apart from ROS generation by
ovarian cancer cells upon treatment with HNTMB, we
observed other cellular responses of SKOV-3 cells to
this chelator such as DNA degradation, arrest of cell
cycle progression in G2/M phase and activation of apop-
totic signaling. Cell cycle regulation is known to be a
target of chelating agents and has been attributed to the
depletion of intracellular iron. Chelators of the AHC
class can regulate the expression of various proteins
involved in cell-cycle control such as CDK2, cyclins A,
B1, D1, D2, D3, WAF1 (inhibitor of CDKs) as shown for
HNI/311 in neuroblastoma and an erythroleukemia cell
line. While chelators such as HNI/311 or DFO generally
block G1/S phase transition, effects on the G2/M transi-
tion during the cell cycle has also been implicated
[58,59]. For DFO and a 3-hydroxypyridin-4-one iron-
chelator, it has been shown in K562 erythroleukemia
cells that at higher concentrations these cells undergo
arrest in G1/S while at lower drug concentrations they
accumulated in G2 and M phase without an effect on
DNA synthesis [60]. Thus, cell cycle regulation through
iron-chelators may depend on the dose and the cell line
studied. HNTMB at 600 nM lead to an accumulation of
SKOV-3 primarily in G2/M phase. Future studies,
beyond the scope of the present work, could focus on
cell cycle checkpoints affected by HNTMB treatment in
synchronized cancer cells and verify the general concept
that iron-chelation (and not depletion of other intracel-
lular metals) is responsible for these effects. Generally,
targeting cell cycle key regulators has been suggested as
a supplemental approach to anti-cancer therapies
[61-64]. In addition, it is noteworthy that cells are most
radiosensitive in the G2/M phase [65]. Based on this
and our findings, HNTMB could be used as a
radiosensitizer.
Drug treatment leading to programmed cell death
(Apoptosis) results in the activation of initiator caspases
which upon activation subsequently activate downstream
effector caspases that are responsible for the cleavage of
many intracellular proteins, leading to the morphologi-
cal and biochemical changes associated with apoptosis
[66,67]. HNTMB treatment of SKOV-3 cells resulted in
strong activation/cleavage of initiator caspase-8 and -9
and of effector caspase-3 and-7, while PARP-1 (involved
in DNA repair) [68] was inactivated/cleaved following
drug treatment. It is noteworthy that HNTMB down-
regulated expression of the X-linked inhibitor of apopto-
sis (XIAP). Down-regulation of XIAP expression in
ovarian cancer cells results in apoptosis in vitro and
prolonged survival of ovarian cancer-bearing mice,
which indicate that XIAP may be a valuable therapeutic
target in ovarian cancers [69]. Interestingly, cisplatin-
resistance in human ovarian surface epithelial (hOSE)
cancer cells is correlated with the inability of cisplatin to
down-regulate XIAP expression [70]. HNTMB may be
an alternative apoptosis inducing drug in certain
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platinum-resistant cancers via XIAP reduction as shown
to occur in SKOV-3 ovarian cancer cells used in the
present study.
HNTMB induced both major signaling pathways
(intrinsic, extrinsic) as evidenced by the activation of
initiator caspases similar to the effect of other iron che-
lators such as tachpyridine, DFO, and dipyridyl [71].
Intrinsic pathway activation may have mitochondrial
damage as a pre-requisite, leading to the activation of
pro-apoptotic members of the Bcl-2 family and/or inac-
tivation of anti-apoptotic Bcl-2 and results in the mito-
chondrial release of cytochrome C which in turn
activates initiator caspase-9 [72] as seen in SKOV-3
cells following HNTMB treatment. It has previously
been suggested that the mitochondrial pathway takes a
center-role in iron chelator-mediated cell death since
over-expression of anti-apoptotic Bcl-2 and Bcl-XL pro-
motes cell (in HeLa cervix carcinoma cells) survival and
chelator-mediated cell death can be blocked by a domi-
nant-negative caspase 9 and Bcl-XL over-expression
[71]. We show here that the exclusive down-regulation
of Bcl-2 expression (in contrast to unmodified Bcl-XL
or Bid) takes a center role in the pro-apoptotic response
of SKOV-3 cells to treatment with HNTMB. Similarly,
other AHC compounds and their iron complexes cause
apoptosis via the mitochondrial pathway (in Jurkat T
cells and K562 leukemia) which could be counteracted
by Bcl-2 overexpression [73]. Because anti-apoptotic
Bcl-2 is highly expressed in various human cancers, this
feature of HNTMB increases its potential as an alterna-
tive anti-tumor drug. Bcl-2 also mediates the resistance
of cancers to conventional therapies such as radio- and
chemo-therapy. Thus, the blockage of Bcl-2 protein
expression by HNTMB treatment could be useful to
sensitize cancer cells to conventional therapies [74]. A
COMPARE analysis using the NCI’s anticancer drug
screen database suggested the involvement of Bcl-2 pro-
tein as a putative target of HNTMB. in its mechanism of
action. The COMPARE computer program utilizes cyto-
toxicity data derived from screening compounds against
60 human cancer cell lines to calculate the Pearson cor-
relation coefficient (positive correlation of 0.45 for
HNTMB), between the data for the seed compound and
those for past agents in the database to identify similar
molecular targets or similar mechanisms of resistance
[75-79].
Induction of apoptosis by chelating agents, including
representatives of AHCs, has been primarily associated
to their capability to bind/deplete intracellular iron [73].
These properties may be especially relevant for cancer
treatment because (i) the intracellular concentration of
iron is generally higher than that of copper and (ii) it
can be significantly elevated in both serum and tumor
tissue of cancer patients with endometrial or breast
cancer [9,10]. The pro-apoptotic effects of non-com-
plexed HNTMB at higher concentrations may be par-
tially linked to its capacity to bind/deplete intracellular
iron. However, it is apparent that a copper/HNTMB
complex at a concentration of 0.4 μl strongly induces
apoptosis, while an iron/HNTMB complex has no such
effects. Observations related to the role of organocopper
complexes in apoptotic events include disruption of the
peroxide and thiol metabolism with subsequent up-reg-
ulation of pro-apoptotic Bcl-2 family members (Bak/Bax
in melanoma and epithelial carcinoma cells) [80]. Pre-
vious studies have revealed that in the presence of com-
plexed copper (Cu-NTA) the expression of anti-
apoptotic Bcl-2 and Bcl-XL can be down-regulated (HL-
60 cells) [81]. Accordingly, the pro-apoptotic activity of
HNTMB may include direct effects on Bcl-2 regulation
when complexed with copper in contrast to the postu-
lated indirect pro-apoptotic effects linked to intracellular
iron depletion. We conclude that non-complexed
HNTMB exerts cytotoxicity on ovarian cancer cells in a
dual function by binding copper [Cu(I) and Cu(II)] pre-
sent in the human body [82] and the intracellular iron
present in the Fe(II) and Fe(III) states [31].
Conclusions
The present report suggests that HNTMB displays prop-
erties akin to an anti-cancer drug and could be an alter-
native to platinum derivatives in the treatment of
ovarian cancer and other solid tumors. HNTMB can
chelate iron and copper of different oxidation states and
possess anti-cancer drug attributes via its properties as a
chelator of intracellular trace-metals or, alternatively, as
a cytotoxic organic metal- (e.g., copper) complex.
HNTMB and other chelating drugs of the lipophilic
aroylhydrazone class may prove to be superior to other
chelators or metal complexes already in use for the
treatment of cancer. Experimental approaches using the
ovarian cancer cell line SKOV-3 as a model system sug-
gest various modes of action exerted by HNTMB based
on the generation of ROS, caspase activation, Bcl-2
down-regulation, DNA degradation and G2/M phase
cell cycle arrest.
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